Sign in Subscribe
Diabetes therapy

GLP-1 Agonists Show Promise in Addressing Cardiovascular-Kidney-Metabolic Syndrome

Strategic Insights

— 1 min read

According to a recent study published in Current Atherosclerosis Reports, glucagon-like peptide-1 receptor (GLP-1R) agonists have emerged as a multifaceted therapeutic option for addressing cardiovascular-kidney-metabolic (CKM) syndrome, microvascular dysfunction, and metabolic-associated steatohepatitis (MASH). These medications, originally developed for glycemic control in diabetes mellitus (DM), are now being explored for their potential to mitigate cardiovascular and metabolic risks in both diabetic and non-diabetic populations.

Key Takeaways:

  • GLP-1R agonists have shown potential in addressing the complex interplay of CKM syndrome, microvascular dysfunction, and MASH, with emerging evidence supporting their use in non-diabetic populations.
  • The growing prevalence of metabolic disease, chronic kidney disease (CKD), and atherosclerotic cardiovascular disease (ASCVD) has prompted investigation into the role of GLP-1R agonists in mitigating cardiovascular and metabolic risks.
  • The mechanistic versatility of GLP-1R agonists has enabled broader application across a spectrum of cardiovascular, cerebrovascular, and metabolic disorders.
  • Combination therapies may enhance efficacy and patient outcomes, and ongoing clinical trials are expected to provide further insights into the translational potential of GLP-1R agonists.
  • Current barriers to implementation and evidence-based use of GLP-1R agonists include lack of clinical education and policy reforms, which must be addressed to optimize their use in both clinical and population health settings.

Statistics:

  • Diabetes mellitus currently affects over 422 million individuals worldwide, with projections indicating a rise to 783 million by 2045, representing 10.5% of the global adult population.
  • Common comorbidities of DM include chronic kidney disease (CKD) and atherosclerotic cardiovascular disease (ASCVD), which collectively impact nearly one-third of individuals with DM.
  • GLP-1R agonists were originally developed for glycemic control in DM, but their mechanistic versatility has enabled broader application across a spectrum of cardiovascular, cerebrovascular, and metabolic disorders.

Sources:

  • NewsRx. Researchers at Brown University Warren Alpert Medical School Report New Data on Diabetes Mellitus (Current Perspectives on GLP-1 Agonists in Contemporary Clinical Practice from Science and Mechanistic Foundations To Optimal Translation). Cardiovascular Week. October 20, 2025; p 517.
  • Current Atherosclerosis Reports. Current Perspectives on GLP-1 Agonists in Contemporary Clinical Practice from Science and Mechanistic Foundations To Optimal Translation. 2025;27(1):99.

Read more